Avoro Capital Advisors — 2012 Investments
2 investments dated 2012 · listed companies and verified rows first · show all
Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).
BiotechHealthtechCambridge, US
MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)
Co-investorsBain Capital Life SciencesF-Prime CapitalLightstone VenturesNew Enterprise Associates (NEA)Nextech InvestPfizer Venture Investments+1 more
Stemline is an oncology-focused pharmaceutical company developing and commercializing cancer therapies, including ELZONRIS (tagraxofusp-erzs) for blastic plasmacytoid dendritic cell neoplasm and ORSERDU (elacestrant) for ER-positive, HER2-negative, ESR-1 mutated advanced or metastatic breast cancer.
BiotechHealthtechNew York, US
Ivan Bergstein, M.D.(Executive Officer, Director)
BoardRonald Bentsur(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.